Non-viral lipid-based delivery of therapeutic DNA for cancer and autoimmune diseases
At the heart of our innovation is the non-viral delivery method, designed to specifically target and modify cells within the patient using therapeutic DNA. Nanocell’s proprietary approach to DNA delivery offers a promising alternative to viral methods, setting a new benchmark in the field.
The NanoCellTx platform stands distinct, employing cell-targeting lipid nanoparticles (t-LNPs) enriched with our proprietary DNA and RNA-transposase technologies. These have been meticulously fine-tuned to optimize gene integration, ensuring long-term therapeutic impact. Another feature of our t-LNPs is their adaptability, and their design can accommodate a wide array of binders, offering a precision targeting of varied cell types.
Beyond the immediate applications in cancer treatment, this versatility paves the way for groundbreaking therapies across diverse medical conditions, spanning from autoimmune and inflammatory diseases to inherited disorders.
We recognize the transformative potential of targeting immune cells in-vivo. This approach adeptly overcomes the challenges often associated with ex-vivo products: from soaring production expenses and extended timelines to potency limits and the inherent toxicity risks of using large volumes of bead-activated cells. It also circumvents the operational intricacies of today’s conventional cell therapy treatment model or protocols. By engineering a select group of non-exhausted effector cells in their natural state to express chimeric antigen or T cell receptors in-vivo, there’s potential to cultivate a robust effector repertoire in individuals with an intact immune system. Such cells are primed to organically thrive, strategically combat cancer cells, and provide enduring protection, building a resilient cellular defence for the future.